Merck & Co Inc (NYSE:MRK)
$ 129.97 -0.41 (-0.31%) Market Cap: 329.19 Bil Enterprise Value: 359.13 Bil PE Ratio: 144.41 PB Ratio: 8.15 GF Score: 85/100

Merck & Co Inc at Goldman Sachs CEOs Unscripted Conference Transcript

Jan 05, 2023 / 01:55PM GMT
Release Date Price: $113.64 (+1.39%)
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, and happy new year to everybody. My name is Chris Shibutani. I'm the U.S. large cap pharmaceuticals analyst, and I also cover some of the biotech and biopharma sector. So I was really pleased to see the expectations for performance out of both of those.

Robert M. Davis
Merck & Co., Inc. - CEO & Chairman

Me, too.

Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Outstanding. We are thrilled to kick off the year. Literally, this is the start of the year, and with Merck being able to be the first voice as the industry and the investor community comes together once again, and we look forward to 2023, where, obviously, expectations for performance there.

Really pleased to have joining with us Rob Davis, CEO, and now Chairman as well, which, I think, is an interesting context. Also our slide should be updated for that. But I also did want to express special thanks to the entire

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot